Clinical Trials Sponsored by Adeona Pharmaceuticals

Total 19842 results

Adeona Pharmaceuticals

Unknown

Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease

Mild Cognitive Impairment | Alzheimer's Disease

United States
Arena Pharmaceuticals

Completed

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis (ELEVATE UC 12)

Ulcerative Colitis

United States, Spain, Israel, Netherlands, Australia, Korea, Republic of, Czechia, Italy, Russian Federation, Croatia, Portugal, Serbia, Belarus, Canada, Georgia, Hungary, Ukraine, Germany, Poland, Belgium, Turkey, Japan, Thailand, India and more
Arena Pharmaceuticals

Completed

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis (ELEVATE UC 52)

Ulcerative Colitis

Israel, Spain, United States, Australia, Denmark, Korea, Republic of, Czechia, Russian Federation, Croatia, Portugal, Serbia, Taiwan, Canada, Bulgaria, Belarus, Georgia, Hungary, Italy, Latvia, Netherlands, Ukraine, Germany, Poland, B... and more
Arena Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis (ADVISE)

Atopic Dermatitis

United States, Australia, Canada
Arena Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Australia, New Zealand
Arena Pharmaceuticals

Completed

Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

Abdominal Pain | Crohn's Disease

United States
Arena Pharmaceuticals

Terminated

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

Inflammatory Bowel Diseases | Skin Extra-intestinal Manifestations

Belgium, Germany, Serbia
Arena Pharmaceuticals

Completed

Single-Dose Safety Study of APD791 in Healthy Volunteers

Healthy

United States
Arena Pharmaceuticals

Terminated

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) (CAPTIVATE)

Irritable Bowel Syndrome

United States
Arena Pharmaceuticals

Completed

A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

Healthy

United States
Arena Pharmaceuticals

Terminated

Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

Pyoderma Gangrenosum

Australia, New Zealand
Arena Pharmaceuticals

Completed

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Ulcerative Colitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Korea, Republic of, Latvia, Lithuania, New Zealand, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
Arena Pharmaceuticals

Completed

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

Smoking Cessation

United States
Arena Pharmaceuticals

Completed

Single-dose Safety Study of APD916 in Healthy Volunteers

Narcolepsy With or Without Cataplexy

United States
Arena Pharmaceuticals

Completed

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Korea, Republic of, Latvia, Lithuania, New Zealand, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
Arena Pharmaceuticals

Terminated

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Arena Pharmaceuticals

Completed

Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia

Primary Insomnia

United States
Arena Pharmaceuticals

Completed

Safety and Efficacy Study of APD125 in Patient With Insomnia

Insomnia

United States
Ultragenyx Pharmaceutical Inc
Abeona Therapeutics, Inc

Enrolling by invitation

A Long-term Follow-up Study of Patients With MPS IIIA Treated With ABO-102

Mucopolysaccharidosis III-A

United States, Australia, Spain
Ultragenyx Pharmaceutical Inc
Abeona Therapeutics, Inc

Terminated

Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease

Mucopolysaccharidosis III | Sanfilippo Syndrome | MPS IIIA | Sanfilippo A

United States, Spain, Australia
Ultragenyx Pharmaceutical Inc
Abeona Therapeutics, Inc

Active, not recruiting

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH

Mucopolysaccharidosis III | Sanfilippo Syndrome | MPS IIIA | Sanfilippo A

United States, Australia, Spain
Abeona Therapeutics, Inc

Completed

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa

United States
Abeona Therapeutics, Inc

Terminated

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

Mucopolysaccharidosis III-B

United States, Germany, France
Abeona Therapeutics, Inc

Enrolling by invitation

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

RDEB

United States
Abeona Therapeutics, Inc

Terminated

Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB (MPSIIIB)

Mucopolysaccharidosis Type 3 B

United States, Germany, France, Spain
Abeona Therapeutics, Inc

Completed

A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

Onychomycosis

United States
Abeona Therapeutics, Inc

Recruiting

EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | RDEB

United States
SIA Adenta

Recruiting

Atraumatic Zirconia Abutment Versus Customized Composite Healing Abutment in Maxilla or Mandible.

Dental Anxiety | Female | Dental Implants | Male | Humans | Osseointegration | Guided Surgery | Dental Implants, Single-Tooth

Latvia
Abeona Therapeutics, Inc
Genaera Corporation

Completed

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Diabetic Foot Ulcers

United States
Abeona Therapeutics, Inc
Genaera Corporation

Completed

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Diabetic Foot Ulcers

United States
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Ospedali Riuniti Ancona

Completed

Early Versus Late Renal Replacement Therapy After Cardiac Surgery

Acute Kidney Injury

Italy
Adela, Inc

Recruiting

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR)

Sarcoma | Lymphoma | Cervical Cancer | Leukemia | Stomach Cancer | Breast Cancer | Head and Neck Cancer | Multiple Myeloma | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Brain Cancer | Bladder Cancer | Endometrial Cancer | Thyroid Cancer | Renal Cancer | Hepatobiliary...

United States
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States

Clinical Trials Sponsored by Adeona Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations